Table 5.

EGFRvIII mutation is associated with disease control

EGFRvIII	Best Response
	Progressive Disease	Disease Control (Partial Response or Stable Disease)
EGFRvIII absent by ΔΔCt	12 (67%)	6 (33%)	P = 0.0099
EGFRvIII present by ΔΔCt	5 (25%)	15 (75%)	(Chi-square)
EGFRvIII mean fold change	10.62	63.76	P = 0.04
EGFRvIII median fold change	3.16	11.11	(Wilcoxon)
Erlotinib treated patients
EGFRvIII absent by ΔΔCt	6 (55%)	5 (45%)	P = 0.21
EGFRvIII present by ΔΔCt	3 (33%)	10 (77%)	(Fisher's)
Non-erlotinib treated patients
EGFRvIII absent by ΔΔCt	6 (86%)	1 (14%)	P = 0.21
EGFRvIII present by ΔΔCt	2 (29%)	5 (71%)	(Fisher's)